🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 1 día
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/04/2025 7,58 8,02 7,56 8,01 +4,30% 6,13% 1.173.700
14/04/2025 8,26 8,36 7,49 7,68 -6,11% 10,53% 1.452.500
11/04/2025 7,45 8,18 7,34 8,18 +9,07% 11,28% 1.197.100
10/04/2025 7,56 7,63 7,13 7,50 -5,54% 6,61% 1.571.500
09/04/2025 6,84 8,14 6,75 7,94 +12,78% 20,32% 1.680.700
08/04/2025 7,36 7,55 6,90 7,04 -3,03% 8,83% 1.241.500
07/04/2025 6,60 7,41 6,50 7,26 +5,68% 13,79% 1.765.200
04/04/2025 7,12 7,31 6,79 6,87 -4,18% 7,30% 1.618.600
03/04/2025 7,55 7,62 7,14 7,17 -9,13% 6,29% 2.072.800
02/04/2025 7,63 7,93 7,62 7,89 +2,33% 4,13% 686.100
01/04/2025 7,81 7,90 7,51 7,71 -1,78% 4,99% 1.020.400
31/03/2025 7,90 8,02 7,56 7,85 -3,92% 5,82% 1.290.300
28/03/2025 8,52 8,57 8,12 8,17 -3,77% 5,28% 468.600
27/03/2025 8,26 8,53 8,14 8,49 +2,78% 4,72% 619.600
26/03/2025 8,35 8,52 8,02 8,26 -1,67% 5,99% 756.500
25/03/2025 9,14 9,14 8,31 8,40 -7,89% 9,08% 721.600
24/03/2025 8,93 9,19 8,93 9,12 +2,01% 2,91% 426.400
21/03/2025 8,94 9,15 8,83 8,94 -1,43% 3,58% 2.190.500
20/03/2025 9,10 9,45 9,04 9,07 -0,22% 4,56% 804.200
19/03/2025 8,82 9,18 8,82 9,09 +1,11% 4,08% 691.000
18/03/2025 9,00 9,23 8,88 8,99 -1,75% 3,89% 657.400
17/03/2025 9,14 9,33 8,95 9,15 -2,03% 4,16% 1.016.200
14/03/2025 9,55 9,69 9,26 9,34 -2,10% 4,45% 542.900
13/03/2025 9,65 9,90 9,45 9,54 -1,65% 4,66% 636.400
12/03/2025 9,87 9,98 9,42 9,70 -2,02% 5,67% 907.700
11/03/2025 9,37 10,03 9,22 9,90 +5,21% 8,64% 1.305.500
10/03/2025 9,45 9,62 9,01 9,41 -1,77% 6,49% 1.579.800
07/03/2025 9,93 10,00 9,50 9,58 -4,39% 5,04% 885.700
06/03/2025 9,56 10,12 9,47 10,02 +2,14% 6,80% 622.600
05/03/2025 9,74 9,90 9,42 9,81 +1,24% 4,93% 1.347.400